CGTX Q3 EPS Estimate Raised by Brookline Capital Management

Key Points

• Brookline Capital Management raised their Q3 2025 earnings estimate for Cognition Therapeutics to (-0.07) per share, an improvement from a previous estimate of (-0.09) per share.
• The stock received mixed analyst ratings, with HC Wainwright maintaining a "buy" rating with a $3.00 target price, while Wall Street Zen downgraded it to a "strong sell."
• Cognition Therapeutics shares have seen significant growth, with a recent increase of 9.3% and a market capitalization of $190.42 million.

Cognition Therapeutics, Inc. (NASDAQ:CGTX - Free Report) - Equities researchers at Brookline Capital Management lifted their Q3 2025 earnings per share estimates for shares of Cognition Therapeutics in a report issued on Tuesday, September 2nd. Brookline Capital Management analyst T. Bussian now expects that the company will earn ($0.07) per share for the quarter, up from their prior estimate of ($0.09). The consensus estimate for Cognition Therapeutics' current full-year earnings is ($0.80) per share. Brookline Capital Management also issued estimates for Cognition Therapeutics' Q4 2025 earnings at ($0.05) EPS and FY2025 earnings at ($0.34) EPS.

Other equities analysts have also issued reports about the company. Chardan Capital restated a "buy" rating and issued a $4.00 target price on shares of Cognition Therapeutics in a research note on Friday, August 8th. Wall Street Zen upgraded Cognition Therapeutics from a "sell" rating to a "hold" rating in a research note on Friday, September 5th. Finally, HC Wainwright restated a "buy" rating and issued a $3.00 target price on shares of Cognition Therapeutics in a research note on Thursday, June 26th. One investment analyst has rated the stock with a Strong Buy rating and three have assigned a Buy rating to the stock. Based on data from MarketBeat.com, Cognition Therapeutics has an average rating of "Buy" and an average target price of $2.83.

Cognition Therapeutics Stock Performance

CGTX remained flat at $2.53 during trading on Friday. The company had a trading volume of 1,351,248 shares, compared to its average volume of 4,889,231. The company has a 50-day simple moving average of $1.32 and a 200-day simple moving average of $0.70. The stock has a market cap of $186.01 million, a P/E ratio of -3.78 and a beta of 1.33. Cognition Therapeutics has a twelve month low of $0.22 and a twelve month high of $3.83.

Cognition Therapeutics (NASDAQ:CGTX - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.12) by $0.01.

Hedge Funds Weigh In On Cognition Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Two Sigma Investments LP boosted its holdings in shares of Cognition Therapeutics by 372.2% in the 4th quarter. Two Sigma Investments LP now owns 53,691 shares of the company's stock worth $38,000 after purchasing an additional 42,321 shares in the last quarter. Northeast Financial Consultants Inc lifted its stake in shares of Cognition Therapeutics by 158.6% in the 1st quarter. Northeast Financial Consultants Inc now owns 63,351 shares of the company's stock valued at $27,000 after acquiring an additional 38,851 shares during the last quarter. CM Management LLC lifted its stake in shares of Cognition Therapeutics by 100.0% in the 1st quarter. CM Management LLC now owns 400,000 shares of the company's stock valued at $168,000 after acquiring an additional 200,000 shares during the last quarter. Finally, Acadian Asset Management LLC lifted its stake in shares of Cognition Therapeutics by 814.1% in the 1st quarter. Acadian Asset Management LLC now owns 1,007,586 shares of the company's stock valued at $422,000 after acquiring an additional 897,353 shares during the last quarter. 43.35% of the stock is currently owned by hedge funds and other institutional investors.

About Cognition Therapeutics

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.